Tenofovir alafenamide: clinical trials recruiting now
3
Recruiting trials
8
Conditions studied
1
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Tenofovir alafenamide appears in the FDA drug-label database. Marketed as VEMLIDY.
- Boxed warning
- The FDA label for Tenofovir alafenamide carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease [see Clinical Studies (14) ] . VEMLIDY is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease. ( 1 )
Phase breakdown
Phase 2 1
Phase 4 1
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Hepatitis B | 2 |
| Acute-On-Chronic Liver Failure | 1 |
| HIV | 1 |
| Healthy Volunteer | 1 |
| Integrase Strand Transfer Inhibitors | 1 |
| Metabolic Effects | 1 |
| Viral Hepatitis | 1 |
| Weight Gain | 1 |
Recruiting trials involving Tenofovir alafenamide
- Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
- Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
- Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
Common questions
Is Tenofovir alafenamide FDA-approved?
Yes, marketed as VEMLIDY. Its FDA label carries a boxed warning.
How many recruiting trials involve Tenofovir alafenamide?
3 recruiting trials across 8 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.